Spectrum downgraded to neutral at B Riley on doubts over approval of poziotinib

Nov. 16, 2022 2:38 PM ETSpectrum Pharmaceuticals, Inc. (SPPI)AMGN, AZNBy: Jonathan Block, SA News Editor

Wall Street New York City

aluxum

  • B Riley has downgraded Spectrum Pharmaceuticals (NASDAQ:SPPI) to neutral from buy citing uncertainty over the approval of poziotinib later this month and a challenging near-term pipeline catalyst profile.
  • The firm also lowered its price target to $1 from $1.50 (~92% upside based on

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.